Sectoral Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sectoral Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,355	Closed	-$111K	–	111
2023 Q4	$111K	Sell	7,355 -379,170	-98%	-$5.53M	0.05%	102
2023 Q3	$7.75M	Buy	386,525 +152,525	+65%	+$3.87M	1.51%	22
2023 Q2	$6.6M	Hold	234,000	–	–	1.1%	35
2023 Q1	$4.02M	Buy	234,000 +33,000	+16%	+$668K	0.77%	55
2022 Q4	$4.05M	Buy	201,000 +141,000	+235%	+$3.03M	0.78%	55
2022 Q3	$1.3M	Buy	+60,000	New	+$1.64M	0.26%	83
2020 Q4	–	Sell	-556,712	Closed	-$18.2M	–	107
2020 Q3	$18.2M	Buy	556,712 +412,512	+286%	+$14.4M	1.56%	25
2020 Q2	$6.92M	Buy	+144,200	New	+$5.53M	0.64%	60

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sectoral Asset Management's ZNTL Position: Q1 2024 in Review

Sectoral Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2024, closing a stake of 7,355 shares — an estimated $111K sold.

Sectoral Asset Management first reported a position in ZNTL in Q2 2020 and held it in 8 quarters. The position peaked at $18.2M in Q3 2020. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

Sectoral Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Sectoral Asset Management sold 7,355 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $111K.
Sectoral Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Sectoral Asset Management's Zentalis Pharmaceuticals position peaked at $18.2M in Q3 2020.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Sectoral Asset Management's 13F filing for Q1 2024, filed 14 May 2024.